Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJOncoAlert Journal Club | Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer

Isotta Martha Magaton • 2 May 2025
VJOncoAlert Journal Club
Breast Cancer

In this latest episode of the VJOncoAlert Journal Club, Isotta Martha Magaton, MD, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, comments on the safety of Assisted Reproductive Technology (ART) in young BRCA1 and 2 carriers with a pregnancy after breast cancer. Dr Megaton highlights that her study, which included 543 young BRCA1 and 2 carriers, found that the use of ART did not appear to be associated with an increased risk of disease-free survival events or adverse pregnancy outcomes, and that ART was not linked to an increased risk of miscarriage or induced abortion.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals